Literature DB >> 15019861

The importance of blood pressure control in the patient with diabetes.

George L Bakris1.   

Abstract

In individuals with diabetes mellitus, higher risk for renal and cardiovascular disease is seen with blood pressure levels >130/80 mm Hg. Findings of several studies, as well as new guidelines, indicate that individuals with diabetes will benefit from more aggressive treatment of hypertension. Angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, diuretics, beta-adrenoceptor blockers, and calcium-channel blockers are effective antihypertensive agents in type 2 diabetes. Moreover, combinations of these agents are frequently required to reach the target blood pressure of <130/80 mm Hg and reduce risk for renal and cardiovascular events. All of these agents have demonstrated benefits in treating patients. Clinical evidence also indicates that the new vasodilating beta-blockers offer advantages beyond blood pressure control, including cardiovascular risk reduction without exacerbating metabolic parameters. With increased awareness of the need for aggressive treatment of hypertension, clinicians can provide significant benefit to their patients with diabetes. The new beta-blockers may play an important role in achieving blood pressure goals.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15019861     DOI: 10.1016/j.amjmed.2003.10.018

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  20 in total

Review 1.  Antihypertensive agents, insulin sensitivity, and new-onset diabetes.

Authors:  Pantelis A Sarafidis; Samy I McFarlane; George L Bakris
Journal:  Curr Diab Rep       Date:  2007-06       Impact factor: 4.810

2.  BP and Renal Outcomes in Diabetic Kidney Disease: The Veterans Affairs Nephropathy in Diabetes Trial.

Authors:  David J Leehey; Jane H Zhang; Nicholas V Emanuele; Adam Whaley-Connell; Paul M Palevsky; Robert F Reilly; Peter Guarino; Linda F Fried
Journal:  Clin J Am Soc Nephrol       Date:  2015-10-19       Impact factor: 8.237

Review 3.  An overview of candesartan in clinical practice.

Authors:  Zeeshan Khawaja; Christopher S Wilcox
Journal:  Expert Rev Cardiovasc Ther       Date:  2011-08

Review 4.  Optimal use of beta-blockers in high-risk hypertension: a guide to dosing equivalence.

Authors:  Janet B McGill
Journal:  Vasc Health Risk Manag       Date:  2010-06-01

Review 5.  Optimizing blood pressure control through the use of fixed combinations.

Authors:  Rainer Düsing
Journal:  Vasc Health Risk Manag       Date:  2010-05-25

Review 6.  Role of ambulatory blood pressure monitoring in hypertension and diabetes.

Authors:  Colleen Flynn; George L Bakris
Journal:  Curr Hypertens Rep       Date:  2013-06       Impact factor: 5.369

7.  Dihydropiridinic Calcium-Channel Antagonists in the 2007 ESH/ESC Hypertension Guidelines.

Authors:  Giuseppe Mancia
Journal:  High Blood Press Cardiovasc Prev       Date:  2013-01-03

8.  Blood pressure-lowering effect of nebivolol in hypertensive patients with type 2 diabetes mellitus: the YESTONO study.

Authors:  Andre C Schmidt; Christine Graf; Klara Brixius; Juergen Scholze
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

9.  Arterial hypertension in diabetes mellitus: from theory to clinical practice.

Authors:  C Sampanis; C Zamboulis
Journal:  Hippokratia       Date:  2008-04       Impact factor: 0.471

10.  Single-pill combination of telmisartan/amlodipine in patients with severe hypertension: results from the TEAMSTA severe HTN study.

Authors:  Joel M Neutel; Giusepe Mancia; Henry R Black; Bjorn Dahlöf; Holly Defeo; Ludwin Ley; Richard Vinisko
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-02-23       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.